Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer

被引:122
作者
Bhangu, A. [2 ]
Ali, S. M. [2 ]
Darzi, A. [3 ]
Brown, G. [4 ]
Tekkis, P. [1 ,2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Colorectal Surg, Div Surg, London SW3 6JJ, England
[2] Royal Marsden Hosp, Dept Colorectal Surg, London SW3 6JJ, England
[3] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Biosurg & Surg Technol, Acad Surg Unit, London SW3 6JJ, England
[4] Royal Marsden Hosp, Dept Radiol, London SW3 6JJ, England
关键词
Recurrent rectal cancer; resection margin; exenteration; TOTAL MESORECTAL EXCISION; SURGICAL-TREATMENT; RADICAL RESECTION; MANAGEMENT; THERAPY; SALVAGE; IMPACT;
D O I
10.1111/j.1463-1318.2012.03005.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Aim To determine the presence and duration of survival advantages was investigated for resection margin status (R0, R1 or R2) following surgery for locally recurrent rectal cancer (LRRC). Method A systematic review of the literature was performed for studies comparing resection margin status for LRRC. Weighted mean differences and meta-analysis of hazard ratios were used as a measure of median and overall cumulative survival. Results Twenty-two studies were included, providing outcome for 1460 patients undergoing surgery for LRRC. 57% underwent an R0 resection, 25% an R1 resection and 11% an R2 resection. The most commonly performed operations were abdominoperineal excision (35%), exenteration (23%) and anterior resection (21%). The range of median survival per resection margin was R0 28-92 months, R1 12-50 months, R2 6-17 months. Patients undergoing an R0 resection survived on average for 37.6 (95% confidence interval: 23.5-51.7) months longer than those undergoing R1 resection and 53.0 (31.2-74.8) months longer than those undergoing R2 resection. This correlated to a hazard ratio of 2.03 (1.73-2.38) for R0 vs R1 and 3.41 (2.21-5.25) for R0 vs R2. Patients undergoing R1 resection survived on average 13.3 (7.23-19.4) months longer than those undergoing R2 resection [hazard ratio of 1.68 (1.33-2.12)]. Conclusion Patients undergoing R0 resection have the greatest survival advantage following surgery for recurrent rectal cancer. There is a survival advantage for R1 over R2 resection, but there may be no benefit of R2 resection over palliative treatment.
引用
收藏
页码:1457 / 1466
页数:10
相关论文
共 41 条
[1]
High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer [J].
Alektiar, KM ;
Zelefsky, MJ ;
Paty, PB ;
Guillem, J ;
Saltz, LB ;
Cohen, AM ;
Minsky, BD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (01) :219-226
[2]
Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: A single institute experience [J].
Asoglu, O. ;
Karanlik, H. ;
Muslumanoglu, M. ;
Igci, A. ;
Emek, E. ;
Ozmen, V. ;
Kecer, M. ;
Parlak, M. ;
Kapran, Y. .
EJSO, 2007, 33 (10) :1199-1206
[3]
International Preoperative Rectal Cancer Management: Staging, Neoadjuvant Treatment, and Impact of Multidisciplinary Teams [J].
Augestad, Knut M. ;
Lindsetmo, Rolv-Ole ;
Stulberg, Jonah ;
Reynolds, Harry ;
Senagore, Anthony ;
Champagne, Brad ;
Heriot, Alexander G. ;
Leblanc, Fabien ;
Delaney, Conor P. .
WORLD JOURNAL OF SURGERY, 2010, 34 (11) :2689-2700
[4]
Surgical treatment of locally recurrent rectal cancer [J].
Bakx, R ;
van Tinteren, H ;
van Lanschot, JJB ;
Zoetmulder, FAN .
EJSO, 2004, 30 (08) :857-863
[5]
Therapy results of locoregional recurrences in rectal cancer [J].
Böhm, B ;
Helfritzsch, H ;
Thiele, M ;
Altendorf-Hofmann, A ;
Scheele, J .
ZENTRALBLATT FUR CHIRURGIE, 2001, 126 (08) :596-600
[6]
Surgery for locally recurrent rectal cancer [J].
Boyle, KM ;
Sagar, PM ;
Chalmers, AG ;
Sebag-Montefiore, D ;
Cairns, A ;
Eardley, I .
DISEASES OF THE COLON & RECTUM, 2005, 48 (05) :929-937
[7]
Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study [J].
Brown, G. ;
Daniels, I. R. ;
Heald, R. J. ;
Quirke, P. ;
Blomqvist, L. ;
Sebag-Montefiore, D. ;
Moran, B. J. ;
Holm, T. ;
Strassbourg, J. ;
Peppercorn, P. D. ;
Fisher, S. E. ;
Mason, B. .
BRITISH MEDICAL JOURNAL, 2006, 333 (7572) :779-782
[8]
Neoadjuvant Accelerated Concomitant Boost Radiotherapy and Multidrug Chemotherapy in Locally Advanced Rectal Cancer A Dose-Escalation Study [J].
Caravatta, Luciana ;
Picardi, Vincenzo ;
Tambaro, Rosa ;
Padula, Gilbert D. A. ;
Macchia, Gabriella ;
Deodato, Francesco ;
Massaccesi, Mariangela ;
Pacelli, Fabio ;
Berardi, Stefano ;
Ridolfini, Marco Pericoli ;
Di Filippo, Loredana ;
Fabrizio, Giovanni ;
Ingrosso, Marcello ;
Cellini, Numa ;
Valentini, Vincenzo ;
Morganti, Alessio G. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (05) :424-431
[9]
METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[10]
High Sacrectomy for Locally Recurrent Rectal Cancer: Can Long-Term Survival Be Achieved? [J].
Dozois, E. J. ;
Privitera, A. ;
Holubar, S. D. ;
Aldrete, J. F. ;
Sim, F. H. ;
Rose, P. S. ;
Walsh, M. F. ;
Bower, T. C. ;
Leibovich, B. C. ;
Nelson, H. ;
Larson, D. W. .
JOURNAL OF SURGICAL ONCOLOGY, 2011, 103 (02) :105-109